Abstract
The study included 24 cases of negative second-look laparotomy (SLL) after operation on ovarian cancer. 12 cases were treated with sizofiran and recombinant interferon-γ before and after SLL and then with human lymphoblastoid interferon-α. The remaining 12 cases (controls) were followed up without any drug therapy after SLL.
There were no recurrences in the treated group, but in 3 cases of the control group.
Also significant difference in survival was noted in the treated group.
Similar content being viewed by others
Abbreviations
- SLL:
-
Second-look laparotomy
- rIFN-γ :
-
recombinant interferon-γ
- HLBI:
-
human lymphoblastoid interferon-α
- Mϕ :
-
macrophage
- CDDP:
-
cisplatin
- ADM:
-
adriamycin
- CPM:
-
cyclophosphamide
- i.m.:
-
intramuscular
- i.p.:
-
intraperitoneal
References
Berek JS, Hacker NF, Lagasse LD, Poth T. Resnick B, Nieberg RK. Second-look laparotomy in stage III epitherial ovarian cancer: Clinical variables associated with disease status. Obstet Gynecol 1984; 64: 207–12.
Cain JM, Saigo BE, Pierce VK et al. A review of second-look laparotomy for ovarian cancer. Gynecol Oncol 1986; 23: 14–25.
Gershenson DM, Copeland LJ, Wharton JT et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985; 55: 1129–35.
Podratz KC, Malkasian GD Jr, Wieand HS, et al. Recurrent disease after negative second-look laparotomy in stage III and IV ovarian carcinoma. Gynecol Oncol 1988; 29: 274–82.
Raju KS, McKinna JA, Baker GM, Wiltshaw E, Jons JM. Second-look operations in the planned management of advanced ovarian carcinoma. Am. J Obstet Gynecol 1982; 144: 650–4.
Matsuo T, Arika T, Mitani M et al. Pharmacological and toxicological studies of a new antitumor polysaccharide, Shizophyllan. Arzneim-Forsch 1982; 32: 647–56.
Tsuchiya Y, Igarashi M, Inoue M et al. Cytokine-related immunomodulating activities of an anti-tumor glucan. J Pharmacobio-Dyn 1989; 12: 616–25.
Billard C, Diez RA, Ferbus D et al. Similar biological effects of different low dose of interferon alpha in cancer patients. Br J Cancer 1987; 55: 677–9.
Marshall ME, Simpson W, Butler K, Fried A, Fer M. Treatment of renal cell carcinoma with daily low-dose alpha-interferon. J Biol Response Mod 1989; 8: 453–61.
Wadler S, Goldman M, Lyver A, Wiernik PH. Phase I trial of 5-fluorouracil and recombinantα2a-interferon in patients with advanced colorectal carcinoma. Cancer Res 1990; 50: 2056–9.
Chen JT, Teshima H, Shimizu Y, Hasumi K, Masubuchi K. Morphological change in human peritoneal macrophages treated with sizofiran or recombinant interferon-γ. Igaku No Ayumi 1989; 150: 505–6.
Lippman SM, Alberts DS, Slymen DJ, et al. Second-look laparotomy in epitherial ovarian carcinoma. Prognostic factors associated with survival duration. Cancer 1988; 61: 2571–7.
Lund B, Williamson P. Prognostic factors for outcome of survival after second-look laparotomy in patients with advanced ovarian carcinoma. Obstet Gynecol 1990; 76: 617–22.
Chambers SK, Chambers JT, Kohorn EI, Lawrence R, Schwartz PE. Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 1988; 72: 404–8.
Creasman WT, Gall S, Bindy BN, Beechman J, Mortel R, Homesley HD. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (A gynecologic oncology group study). Gynecol Oncol 1989; 35: 378–82.
Podratz KC, Schray MF, Wieand HS, et al. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988; 31: 9–21.
Schwartz PE, Smith JP. Second-look operations in ovarian cancer. Am J Obstet Gynecol 1980; 138: 1124–30.
Simpson HL, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 1976; 60: 1749–60.
Podoratz KC, Malkasian GD, Hilton JF, Harris EA, Gaffey TA. Second-look laparotomy in ovarian cancer: Evaluation of pathologic variables. Am J Obstet Gynecol 1985; 152: 230–8.
Barnhill DR, Hoskins WJ, Heller PB, Park RC. The second-look surgical reassessment for epithelial ovarian carcinoma. Gynecol Oncol 1984; 19: 148–54.
Ghatage P, Krepart GV, Lotocki R. Factor analysis of false-negative second-look laparotomy. Gynecol Oncol 1990; 36: 172–5.
Dauplat J, Ferriere JP, Gorbinet M et al. Second-look laparotomy in managing epitherial ovarian carcinoma. Cancer 1986; 57: 1627–31.
Ochiai K. Reassessment of second look operation (SLO) in the treatment of ovarian cancer patients. Jpn J Cancer Chemother 1989; 16 (PART-II): 1303–9.
Freedman RS. Recent immunologic advances affecting the management of ovarian cancer. Clin Obstet Gynecol 1985; 28: 853–71.
Chen JT, Teshima H, Shimizu Y, Hasumi K, Masubuchi K. Effect of sizofiran or recommbinant interferon gamma on the activation of human peritoneal macrophage function; An approach for the prophylaxis of intraperitoneal recurrence of ovarian cancer. Acta Obst Gynaec Jpn 1990; 42: 179–84.
Chen JT, Teshima H, Shimizu Y, Hasumi K, Masubuchi K, Suzuki M. Sizofiran and recombinant interferon gamma stimulate peritoneal macrophages obtained from patients with gynecologic malignacies. - Increased secretion of tumor necrosis factor, IL-1 and interferon gamma. Jpn J. Cancer Chemother 1990; 17: 1365–69.
Chen JT, Hasumi K, Masubuchi K. Maintenance of the activation of peritoneal macrophage in patients with ovarian cancer by the repeat dosing of sizofiran and recombinant interferon-γ in combination. Biotherapy 1992; 5: 137–43.
Salmon SE, Durie BG, Young L, Liu RM, Trown PW, Stebbing N. Effects of cloned human leukocyte interferons in the human stem cell assay. J. Clin Oncol 1983; 1: 217–25.
Welander CE. Interferon in the treatment of ovarian cancer. Semin Oncol 1988; 15: 26–9.
Berek JS, Hacker NF, Lichtenstein A, et al. Intraperitoneal recombinant alpha-interferon for ‘salvage’ immunotherapy in stage III epitherial ovarian cancer. A gynecologic Oncology Group Study. Cancer Res 1985; 45: 4447–53.
Hacker NF, Lawton FG, Astbury LD, Penny R. Intraperitoneal interferon-alpha-2b for patients with a macroscopically negative second-look laparotomy. A preliminary report. In: Sharp F, Mason WP, Leake RE, eds: Ovarian Cancer: Biological and Therapeutic Challenges. London: Chapman & Hall Medical, 1990: 365–9.
Willemse PHB, De Vries EGE, Mulder NH, Aalders JG, Bouma J, Sleijfer DTH. Intraperitoneal human recombinant interferon alpha -2b in minimal residual ovarian cancer. Eur J Cancer 1990; 26: 353–8.
Kirkwood JM, Harris JE, Vera R et al. A randomized study of low and high doses of leukocyteα-interferon in metastatic renal cell carcinoma. The American Cancer Society Collaborative trial. Cancer Res 1985; 45: 863–71.
Johnson HM, Smith BG, Baron S. Inhibition of the primary in vitro antibody response by interferon preparations. J Immunol 1975; 114: 403–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chen, JT., Hasumi, K. & Masubuchi, K. Interferon-α, interferon-γ and sizofiran in the adjuvant therapy in ovarian cancer — a preliminary trial. Biotherapy 5, 275–280 (1992). https://doi.org/10.1007/BF02179044
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02179044